Family Management Corp Sells 1,266 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Family Management Corp decreased its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 7.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,766 shares of the biopharmaceutical company’s stock after selling 1,266 shares during the period. Family Management Corp’s holdings in Pfizer were worth $418,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer during the 4th quarter worth about $26,000. Clarity Asset Management Inc. bought a new position in Pfizer during the 4th quarter valued at about $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at about $28,000. Finally, Noble Wealth Management PBC bought a new stake in Pfizer during the fourth quarter worth about $31,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.5 %

Shares of NYSE:PFE opened at $22.78 on Thursday. The company has a 50 day moving average of $24.15 and a 200-day moving average of $25.65. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock has a market cap of $129.18 billion, a price-to-earnings ratio of 16.15, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the previous year, the company posted $0.82 EPS. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.55%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

View Our Latest Stock Report on PFE

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).